LeMaitre Vascular (NASDAQ:LMAT) Issues Q1 2026 Earnings Guidance

LeMaitre Vascular (NASDAQ:LMAT) updated its first quarter 2026 earnings guidance on Wednesday. The company provided EPS guidance of 0.640-0.690 for the period, compared to the consensus EPS estimate of 0.620. The company issued revenue guidance of $65.6 million-$67.6 million, compared to the consensus revenue estimate of $65.9 million. LeMaitre Vascular also updated its FY 2026 guidance to 2.810-3.010 EPS.

LeMaitre Vascular Stock Up 0.7%

Shares of LeMaitre Vascular stock traded up $0.63 during trading on Wednesday, hitting $91.38. 198,904 shares of the stock traded hands, compared to its average volume of 145,199. The stock has a market cap of $2.07 billion, a P/E ratio of 39.39, a PEG ratio of 2.03 and a beta of 0.72. The company has a fifty day moving average price of $85.86 and a two-hundred day moving average price of $88.09. LeMaitre Vascular has a twelve month low of $71.42 and a twelve month high of $105.55. The company has a debt-to-equity ratio of 0.44, a quick ratio of 11.45 and a current ratio of 13.58.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on LMAT shares. Cantor Fitzgerald reissued a “neutral” rating and issued a $95.00 price objective on shares of LeMaitre Vascular in a research note on Monday, November 10th. Wall Street Zen raised shares of LeMaitre Vascular from a “hold” rating to a “buy” rating in a report on Saturday. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of LeMaitre Vascular in a research report on Monday, December 29th. Roth Mkm reissued a “buy” rating and issued a $108.00 price objective on shares of LeMaitre Vascular in a research report on Wednesday, November 5th. Finally, Barrington Research reaffirmed an “outperform” rating and set a $95.00 target price on shares of LeMaitre Vascular in a research report on Friday, February 20th. Four equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $100.20.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Royal Bank of Canada boosted its stake in LeMaitre Vascular by 1.5% in the first quarter. Royal Bank of Canada now owns 114,176 shares of the medical instruments supplier’s stock valued at $9,579,000 after acquiring an additional 1,735 shares during the last quarter. AQR Capital Management LLC grew its stake in shares of LeMaitre Vascular by 36.4% during the first quarter. AQR Capital Management LLC now owns 27,878 shares of the medical instruments supplier’s stock worth $2,339,000 after purchasing an additional 7,445 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in LeMaitre Vascular by 4.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,078 shares of the medical instruments supplier’s stock valued at $1,013,000 after buying an additional 539 shares during the period. Millennium Management LLC boosted its holdings in LeMaitre Vascular by 119.8% during the first quarter. Millennium Management LLC now owns 211,222 shares of the medical instruments supplier’s stock worth $17,722,000 after buying an additional 115,141 shares during the last quarter. Finally, Goldman Sachs Group Inc. increased its stake in shares of LeMaitre Vascular by 27.0% in the 1st quarter. Goldman Sachs Group Inc. now owns 262,445 shares of the medical instruments supplier’s stock valued at $22,019,000 after acquiring an additional 55,804 shares during the last quarter. 84.64% of the stock is currently owned by institutional investors and hedge funds.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.